Corporate Overview

Brooklyn ImmunoTherapeutics (BTX) creates transformative regenerative medicine treatments for cancer, blood disorders and monogenic diseases. A diversified product line based on foundational iPSC, mRNA, gene editing and non-viral delivery technologies offers multiple clinical applications with future sub-licensing and partnering opportunities.

BTX recruited an experienced leadership team with deep expertise in cell and gene therapy products who manage the development of our platform technologies -- Allogeneic Stem Cell Platform (iMSC), Gene-edited Allogeneic Stem Cell Platform (iMSC), Autologous Cell Therapy Platform, In Vivo Gene Editing Platform, and Mixed Human Cytokine product – in various stages of development from discovery to clinical trials.

BTX’s most advanced program, now in a Phase 2b clinical trial, studies the safety and efficacy of IRX-2, a human cell-derived mixed cytokine therapeutic, in patients with head and neck cancer. In a Phase 2a study, IRX-2 demonstrated an overall survival benefit and was well-tolerated by patients. The ongoing Phase 2b study is expected to report results in Q2 2022. Additional studies are underway in other solid tumor cancer indications as a monotherapy and in combination with other anti-cancer therapies.

Latest Presentation

Latest Events

View All Events